GC511B
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GC511B, covering 2025-11-25 to 2025-11-25. Get the full timeline:
Most recent: Clinical Trial Update: This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. [Phase 1]